The FDA granted orphan drug designation to deupirfenidone, also known as LYT-100, for treating patients with idiopathic pulmonary fibrosis, according to a press release from PureTech Health.The ...

Targeting ACVRL1, dubbed an 'overlooked' gene by researchers, could potentially lead to new treatments for IPF, a study suggests.

Deupirfenidone, a potential new treatment for idiopathic pulmonary fibrosis, is set to be tested in a phase 3 trial this year after a successful phase 2b trial and meeting with the FDA, according to a ...

Of 14 metabolites identified, 2 appeared to have “robust” causal relationships with idiopathic pulmonary fibrosis. Fourteen metabolites appeared to have a causal relationship with idiopathic pulmonary ...